Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-15-Speech-2-571-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110215.29.2-571-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Madam President, unfortunately, we are seeing more and more falsified medicinal products on the market in our Member States. That is why this proposal is so important. Patients in the EU need to know how they can avoid falsified medicinal products. They are also entitled to see that we, as legislators, are fighting to combat these products. It is important that we adopt clear definitions. All too often, we adopt legislation that is imprecise and unclear. This must not happen in such an important case as this. Medicinal products must be checked before they come onto the market and not only after patients have, in fact, been acting as guinea pigs for several years. We must satisfy ourselves that medicinal products are only imported if safety and the possibility of verification are given top priority. Falsification of medicinal products harms both the patients and the pharmaceutical companies in the Member States. I therefore hope that we can agree on a more stringent line than that proposed by the Commission, and I would like to thank Mrs Matias for her sterling work."@en1
|
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples